Table 1. Breast Cancer Biomarkers to Guide Adjuvant Therapy
Test
ER/PgR-positive,
HER2-negative
(node-negative)
ER/PgR-positive,
HER2-negative
(node-positive)
HER2-positive
or TN
Oncotype DX Yes No No
Endopredict Yes No No
MammaPrint
Yes
a
Yes
b
No
Pam50 Yes No No
Mammostrat No No No
Breast Cancer Index Yes No No
IHC4 No No No
Urokinase plasminogen
activator and
plasminogen activator
inhibitor type 1
Yes – No
Circulating Tumor
Cells
No No No
Tumor-Infiltrating
Lymphocytes
No No No
Protein Encoded
Mk167 Gene
No No No
a
In patients with high clinical risk per MINDACT categorization.
b
In patients with 1–3 positive nodes and high clinical risk per MINDACT categorization.
Trastuzumab
➤ If a patient has HER2-positive breast cancer, the clinician should NOT
use phosphatase and tensin homolog (PTEN) to guide adjuvant therapy
selection. (Moderate Recommendation; EB-I)
➤ If a patient has HER2-positive breast cancer, the clinician should NOT
use soluble HER2 levels to guide selection of type of adjuvant therapy.
(Moderate Recommendation; EB-L)
